Patent · US Active

Method for treating cancer with an antibody to CD223 protein

US9005629B2 · kind B2 · utility

38Cited by

13References

4Claims

0Family size

Assignees

St. Jude Children's Research Hospital, Inc. · US
THE JOHNS HOPKINS UNIVERSITY · US

Inventors

Drew M. Pardoll · Silver Spring, US
Ching-Tai Huang · Taipei, TW
Jonathan Powell · Baltimore, US
Charles G. Drake · Baltimore, US
Dario A. Vignali · Germantown, US
Creg J. Workman · Memphis, US

Key dates

Filing date	Nov 16, 2012
Grant date	Apr 14, 2015
Priority date	—
Expiry date	Mar 31, 2033

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Mammals with cancer are treated with an antibody which specifically binds to CD223 protein and inhibits negative T cell regulatory function of CD223. The mammal may be a human. The antibody may be a monoclonal antibody. The amount of the antibody administered may be sufficient to enhance an immune T cell response to the cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.